Choi Eun-Jeong, Koo Yu-Jin, Jeon Ji-Hyun, Kim Tae-Jin, Lee Ki-Heon, Lim Kyung-Taek
Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
Obstet Gynecol Sci. 2014 Jul;57(4):274-80. doi: 10.5468/ogs.2014.57.4.274. Epub 2014 Jul 15.
We sought to investigate the clinicopathologic features of ovarian squamous cell carcinomas arising from mature cystic teratomas (MCT) and to report our clinical experience and lessons learned.
From January 1993 to November 2012, a total of 6,260 women with ovarian MCT were surgically treated at Cheil General Hospital and Women's Healthcare Center. Among them, the cases with malignant transformation to squamous cell carcinoma were included in this analysis. Patient demographic characteristics, surgical findings, and prognosis were evaluated retrospectively.
Of the 6,260 ovarian MCT patients, four (0.06%) had ovarian squamous cell carcinoma arising from MCT. The mean patient age was 43 years (range, 35-51 years), and the mean tumor size was 12 cm (range, 9-16 cm), with two patients in the International Federation of Gynecology and Obstetrics stage I and the other two in stage III. Upon preoperative imaging, all cases were expected to be benign ovarian tumors, but the preoperative squamous cell carcinoma antigen level was elevated from 1.5 ng/mL in stage Ia to 11.3 ng/mL in stage IIIc, suggesting malignancy, while the CA-125 level was normal in two of the three patients who received the test. Optimal debulking surgery was performed and adjuvant chemotherapy was used in all patients, but death from the recurrence of disease occurred in one patient, whose overall survival was 10 months.
Ovarian squamous cell carcinoma arising from MCT is extremely rare, and it is rarely diagnosed preoperatively on imaging workups. Measuring the squamous cell carcinoma antigen level might be a useful diagnostic clue, and it might also be predictive of the tumor stage. An adequate staging surgery should be included in the standard treatment, but multicenter studies are needed to confirm this.
我们试图研究源自成熟囊性畸胎瘤(MCT)的卵巢鳞状细胞癌的临床病理特征,并报告我们的临床经验及所吸取的教训。
1993年1月至2012年11月,共有6260例患有卵巢MCT的女性在首尔圣母医院和妇女医疗中心接受了手术治疗。其中,发生恶性转化为鳞状细胞癌的病例纳入本分析。回顾性评估患者的人口统计学特征、手术结果及预后。
在6260例卵巢MCT患者中,有4例(0.06%)发生了源自MCT的卵巢鳞状细胞癌。患者平均年龄为43岁(范围35 - 51岁),肿瘤平均大小为12 cm(范围9 - 16 cm),国际妇产科联盟分期中2例为I期,另2例为III期。术前影像学检查时,所有病例均被认为是良性卵巢肿瘤,但术前鳞状细胞癌抗原水平从Ia期的1.5 ng/mL升高至IIIc期的11.3 ng/mL,提示恶性,而接受检测的3例患者中有2例CA - 125水平正常。所有患者均进行了最佳肿瘤细胞减灭术并使用了辅助化疗,但有1例患者因疾病复发死亡,其总生存期为10个月。
源自MCT的卵巢鳞状细胞癌极为罕见,术前影像学检查很少能诊断出来。检测鳞状细胞癌抗原水平可能是一个有用的诊断线索,也可能有助于预测肿瘤分期。标准治疗应包括充分的分期手术,但需要多中心研究来证实这一点。